Revising Pharmacokinetics of Oral Drug Absorption: II Bioavailability-Bioequivalence Considerations

Pavlos Chryssafidis,Athanasios A. Tsekouras,Panos Macheras

DOI: https://doi.org/10.1007/s11095-021-03078-w

IF: 4.58

2021-08-01

Pharmaceutical Research

Abstract:<span class="a-plus-plus abstract-section id-a-sec1"><h3 class="a-plus-plus">Purpose</h3><p class="a-plus-plus">To explore the application of the parameters of the physiologically based finite time pharmacokinetic&nbsp;(PBFTPK) models subdivided in&nbsp;first-order&nbsp;(PBFTPK)<sub class="a-plus-plus">1</sub>&nbsp;and zero-order (PBFTPK)<sub class="a-plus-plus">0</sub>&nbsp;models to bioavailability and bioequivalence. To develop a methodology for the estimation of absolute bioavailability, <em class="a-plus-plus">F,</em> from oral data exclusively.</p></span><span class="a-plus-plus abstract-section id-a-sec2"><h3 class="a-plus-plus">Methods</h3><p class="a-plus-plus">Simulated concentration time data were generated from the Bateman equation and compared with data generated from the (PBFTPK)<sub class="a-plus-plus">1&nbsp;</sub>and (PBFTPK)<sub class="a-plus-plus">0</sub>&nbsp;models. The blood concentration <em class="a-plus-plus">C</em><sub class="a-plus-plus"><em class="a-plus-plus">b</em></sub><em class="a-plus-plus">(τ)</em> at the end of the absorption process&nbsp;τ, was compared to <em class="a-plus-plus">C</em><sub class="a-plus-plus"><em class="a-plus-plus">max</em></sub>; the utility of <span class="a-plus-plus inline-equation id-i-eq1"><span class="a-plus-plus equation-source format-t-e-x"><span class="mjpage"><svg xmlns:xlink="http://www.w3.org/1999/xlink" width="8.183ex" height="3.009ex" style="vertical-align: -1.005ex;" viewBox="0 -863.1 3523.4 1295.7" role="img" focusable="false" xmlns="http://www.w3.org/2000/svg"><g stroke="currentColor" fill="currentColor" stroke-width="0" transform="matrix(1 0 0 -1 0 0)"> <use xlink:href="#MJMAIN-28" x="0" y="0"></use> <use xlink:href="#MJMATHI-41" x="389" y="0"></use> <use xlink:href="#MJMATHI-55" x="1140" y="0"></use> <use xlink:href="#MJMATHI-43" x="1907" y="0"></use> <use xlink:href="#MJMAIN-29" x="2668" y="0"></use> <use transform="scale(0.707)" xlink:href="#MJMATHI-3C4" x="4323" y="675"></use> <use transform="scale(0.707)" xlink:href="#MJMAIN-30" x="4323" y="-405"></use></g></svg></span></span></span>&nbsp;and <span class="a-plus-plus inline-equation id-i-eq2"><span class="a-plus-plus equation-source format-t-e-x"><span class="mjpage"><svg xmlns:xlink="http://www.w3.org/1999/xlink" width="8.977ex" height="3.176ex" style="vertical-align: -1.005ex;" viewBox="0 -934.9 3865 1367.4" role="img" focusable="false" xmlns="http://www.w3.org/2000/svg"><g stroke="currentColor" fill="currentColor" stroke-width="0" transform="matrix(1 0 0 -1 0 0)"> <use xlink:href="#MJMAIN-28" x="0" y="0"></use> <use xlink:href="#MJMATHI-41" x="389" y="0"></use> <use xlink:href="#MJMATHI-55" x="1140" y="0"></use> <use xlink:href="#MJMATHI-43" x="1907" y="0"></use> <use xlink:href="#MJMAIN-29" x="2668" y="0"></use> <use transform="scale(0.707)" xlink:href="#MJMAIN-221E" x="4323" y="675"></use> <use transform="scale(0.707)" xlink:href="#MJMATHI-74" x="4323" y="-405"></use></g></svg></span></span></span> in bioequivalence assessment was also explored. Equations for the calculation of <em class="a-plus-plus">F</em> from oral data were derived for&nbsp;the (PBFTPK)<sub class="a-plus-plus">1</sub>&nbsp;and (PBFTPK)<sub class="a-plus-plus">0</sub>&nbsp;models. An estimate for <em class="a-plus-plus">F</em> was also derived from an areas proportionality using oral data exclusively.</p></span><span class="a-plus-plus abstract-section id-a-sec3"><h3 class="a-plus-plus">Results</h3><p class="a-plus-plus">The simulated data of the (PBFTPK)<sub class="a-plus-plus">0</sub>&nbsp;models exhibit rich dynamics encountered in complex drug absorption phenomena. Both (PBFTPK)<sub class="a-plus-plus">1</sub>&nbsp;and (PBFTPK)<sub class="a-plus-plus">0</sub>&nbsp;models result either in <em class="a-plus-plus">C</em><sub class="a-plus-plus"><em class="a-plus-plus">max</em></sub>&nbsp;<em class="a-plus-plus">= C</em><sub class="a-plus-plus"><em class="a-plus-plus">b</em></sub><em class="a-plus-plus">(τ)</em> or <em class="a-plus-plus">C</em><sub class="a-plus-plus"><em class="a-plus-plus">max</em></sub>&nbsp;<em class="a-plus-plus">&gt; C</em><sub class="a-plus-plus"><em class="a-plus-plus">b</em></sub><em class="a-plus-plus">(τ)&nbsp;</em>for rapidly- and not rapidly-absorbed drugs, respectively; in the latter case, <em class="a-plus-plus">C</em><sub class="a-plus-plus"><em class="a-plus-plus">b</em></sub><em class="a-plus-plus">(τ)</em> and&nbsp;τ are meaningful parameters for drug's rate of exposure. For both (PBFTPK)<sub class="a-plus-plus">1</sub>&nbsp;and (PBFTPK)<sub class="a-plus-plus">0</sub>&nbsp;models,&nbsp;<span class="a-plus-plus inline-equation id-i-eq3"><span class="a-plus-plus equation-source format-t-e-x"><span class="mjpage"><svg xmlns:xlink="http://www.w3.org/1999/xlink" width="8.183ex" height="3.009ex" style="vertical-align: -1.005ex;" viewBox="0 -863.1 3523.4 1295.7" role="img" focusable="false" xmlns="http://www.w3.org/2000/svg"><g stroke="currentColor" fill="currentColor" stroke-width="0" transform="matrix(1 0 0 -1 0 0)"> <use xlink:href="#MJMAIN-28" x="0" y="0"></use> <use xlink:href="#MJMATHI-41" x="389" y="0"></use> <use xlink:href="#MJMATHI-55" x="1140" y="0"></use> <use xlink:href="#MJMATHI-43" x="1907" y="0"></use> <use xlink:href="#MJMAIN-29" x="2668" y="0"></use> <use transform="scale(0.707)" xlink:href="#MJMATHI-3C4" x="4323" y="675"></use> <use transform="scale(0.707)" xlink:href="#MJMAIN-30" x="4323" y="-405"></use></g></svg></span></span></span>&nbsp;or portions of it cannot be used as early exposure rate indicators. <span class="a-plus-plus inline-equation id-i-eq4"><span class="a-plus-plus equation-source format-t-e-x"><span class="mjpage"><svg xmlns:xlink="http://www.w3.org/1999/xlink" width="8.977ex" height="3.176ex" style="vertical-align: -1.005ex;" viewBox="0 -934.9 3865 1367.4" role="img" focusable="false" xmlns="http://www.w3.org/2000/svg"><g stroke="currentColor" fill="currentColor" stroke-width="0" transform="matrix(1 0 0 -1 0 0)"> <use xlink:href="#MJMAIN-28" x="0" y="0"></use> <use xlink:href="#MJMATHI-41" x="389" y="0"></use> <use xlink:href="#MJMATHI-55" x="1140" y="0"></use> <use xlink:href="#MJMATHI-43" x="1907" y="0"></use> <use xlink:href="#MJMAIN-29" x="2668" y="0"></use> <use transform="scale(0.707)" xlink:href="#MJMAIN-221E" x="4323" y="675"></use> <use transform="scale(0.707)" xlink:href="#MJMATHI-3C4" x="4323" y="-405"></use></g></svg></span></span></span>&nbsp;is a useful parameter for the assessment of extent of absorption for very rapidly absorbed drugs. An estimate for <em class="a-plus-plus">F</em> for theophylline formulations was found close to unity.</p></span><span class="a-plus-plus abstract-section id-a-sec4"><h3 class="a-plus-plus">Conclusion</h3><p class="a-plus-plus">The (PBFTPK)<sub class="a-plus-plus">1</sub>&nbsp;and (PBFTPK)<sub class="a-plus-plus">0</sub>&nbsp;models are more akin to <em class="a-plus-plus">in vivo</em> conditions. Estimates for <em class="a-plus-plus">F</em> can be derived from oral data exclusively.</p></span><svg xmlns="http://www.w3.org/2000/svg" style="display: none;"><defs id="MathJax_SVG_glyphs"><path stroke-width="1" id="MJMAIN-28" d="M94 250Q94 319 104 381T127 488T164 576T202 643T244 695T277 729T302 750H315H319Q333 750 333 741Q333 738 316 720T275 667T226 581T184 443T167 250T184 58T225 -81T274 -167T316 -220T333 -241Q333 -250 318 -250H315H302L274 -226Q180 -141 137 -14T94 250Z"></path><path stroke-width="1" id="MJMATHI-41" d="M208 74Q208 50 254 46Q272 46 272 35Q272 34 270 22Q267 8 264 4T251 0Q249 0 239 0T205 1T141 2Q70 2 50 0H42Q35 7 35 11Q37 38 48 46H62Q132 49 164 96Q170 102 345 401T523 704Q530 716 547 716H555H572Q578 707 578 706L606 383Q634 60 636 57Q641 46 701 46Q726 46 726 36Q726 34 723 22Q720 7 718 4T704 0Q701 0 690 0T651 1T578 2Q484 2 455 0H443Q437 6 437 9T439 27Q443 40 445 43L449 46H469Q523 49 533 63L521 213H283L249 155Q208 86 208 74ZM516 260Q516 271 504 416T490 562L463 519Q447 492 400 412L310 260L413 259Q516 259 516 260Z"></path><path stroke-width="1" id="MJMATHI-55" d="M107 637Q73 637 71 641Q70 643 70 649Q70 673 81 682Q83 683 98 683Q139 681 234 681Q268 681 297 681T342 682T362 682Q378 682 378 672Q378 670 376 658Q371 641 366 638H364Q362 638 359 638T352 638T343 637T334 637Q295 636 284 634T266 623Q265 621 238 518T184 302T154 169Q152 155 152 140Q152 86 183 55T269 24Q336 24 403 69T501 205L552 406Q599 598 599 606Q599 633 535 637Q511 637 511 648Q511 650 513 660Q517 676 519 679T529 683Q532 683 561 682T645 680Q696 680 723 681T752 682Q767 682 767 672Q767 650 759 642Q756 637 737 637Q666 633 648 597Q646 592 598 404Q557 235 548 205Q515 105 433 42T263 -22Q171 -22 116 34T60 167V183Q60 201 115 421Q164 622 164 628Q164 635 107 637Z"></path><path stroke-width="1" id="MJMATHI-43" d="M50 252Q50 367 117 473T286 641T490 704Q580 704 633 653Q642 643 648 636T656 626L657 623Q660 623 684 649Q691 655 699 663T715 679T725 690L740 705H746Q760 705 760 698Q760 694 728 561Q692 422 692 421Q690 416 687 415T669 413H653Q647 419 647 422Q647 423 648 429T650 449T651 481Q651 552 619 605T510 659Q484 659 454 652T382 628T299 572T226 479Q194 422 175 346T156 222Q156 108 232 58Q280 24 350 24Q441 24 512 92T606 240Q610 253 612 255T628 257Q648 257 648 248Q648 243 647 239Q618 132 523 55T319 -22Q206 -22 128 53T50 252Z"></path><path stroke-width="1" id="MJMAIN-29" d="M60 749L64 750Q69 750 74 750H86L114 726Q208 641 251 514T294 250Q294 182 284 119T261 12T224 -76T186 -143T145 -194T113 -227T90 -246Q87 -249 86 -250H74Q66 -250 63 -250T58 -247T55 -238Q56 -237 66 -225Q221 -64 221 250T66 725Q56 737 55 738Q55 746 60 749Z"></path><path stroke-width="1" id="MJMATHI-3C4" d="M39 284Q18 284 18 294Q18 301 45 338T99 398Q134 425 164 429Q170 431 332 431Q492 431 497 429Q517 424 517 402Q517 388 508 376T485 360Q479 358 389 358T299 356Q298 355 283 274T251 109T233 20Q228 5 215 -4T186 -13Q153 -13 153 20V30L203 192Q214 228 227 272T248 336L254 357Q254 358 208 358Q206 358 197 358T183 359Q105 359 61 295Q56 287 53 286T39 284Z"></path><path stroke-width="1" id="MJMAIN-30" d="M96 585Q152 666 249 666Q297 666 345 640T423 548Q460 465 460 320Q460 165 417 83Q397 41 362 16T301 -15T250 -22Q224 -22 198 -16T137 16T82 83Q39 165 39 320Q39 494 96 585ZM321 597Q291 629 250 629Q208 629 178 597Q153 571 145 525T137 333Q137 175 145 125T181 46Q209 16 250 16Q290 16 318 46Q347 76 354 130T362 333Q362 478 354 524T321 597Z"></path><path stroke-width="1" id="MJMAIN-221E" d="M55 217Q55 305 111 373T254 442Q342 442 419 381Q457 350 493 303L507 284L514 294Q618 442 747 442Q833 442 888 374T944 214Q944 128 889 59T743 -11Q657 -11 580 50Q542 81 506 128L492 147L485 137Q381 -11 252 -11Q166 -11 111 57T55 217ZM907 217Q907 285 869 341T761 397Q740 397 720 392T682 378T648 359T619 335T594 310T574 285T559 263T548 246L543 238L574 198Q605 158 622 138T664 94T714 61T765 51Q827 51 867 100T907 217ZM92 214Q92 145 131 89T239 33Q357 33 456 193L425 233Q364 312 334 337Q285 380 233 380Q171 380 132 331T92 214Z"></path><path stroke-width="1" id="MJMATHI-74" d="M26 385Q19 392 19 395Q19 399 22 411T27 425Q29 430 36 430T87 431H140L159 511Q162 522 166 540T173 566T179 586T187 603T197 615T211 624T229 626Q247 625 254 615T261 596Q261 589 252 549T232 470L222 433Q222 431 272 431H323Q330 424 330 420Q330 398 317 385H210L174 240Q135 80 135 68Q135 26 162 26Q197 26 230 60T283 144Q285 150 288 151T303 153H307Q322 153 322 145Q322 142 319 133Q314 117 301 95T267 48T216 6T155 -11Q125 -11 98 4T59 56Q57 64 57 83V101L92 241Q127 382 128 383Q128 385 77 385H26Z"></path></defs></svg>

pharmacology & pharmacy,chemistry, multidisciplinary